Optimal use of hyaluronic acid for joint pathology treatment
Popov V.P.1,2, Koroshchenko S.A.2, Larin M.A.1
1 Siberian State Medical University, Tomsk
2 Seversk Clinical Hospital, Seversk, Tomsk Region
Osteoarthrosis (OA) is a common disease, resulting in the long-term disability and often resulting in the permanent disability of the patient. Hyaluronic acid (HA) provides positive effect on the functional state of the joint and the reduction of the pain syndrome. To obtain a therapeutic effect, the intra-articular administration of HA is used, there are some reports on the use of extra-articular administration of these drugs.
Aim: to evaluate the possibility of paraarticular administration (PA) of the HA containing drug Fermatron 1% and to make a comparative evaluation of this method of treatment with intraarticular administration (IA).
Patients and methods: 148 patients of both genders aged 59 ± 3.5 years with OA of hip and knee joints of 1-2 degree were included in the study. The drug Fermatron 1% was used for the treatment. The patients were divided into 2 groups: group 1 included 84 patients, the treatment was performed by the administration of the drug, group 2 included 64 patients, the drug was injected by PA. The dynamics of joints was studied for the severity of the pain syndrome before the treatment and 1 month after the completion of treatment.
Results: in 96.4% of patients, joint pain significantly decreased. In 85.7% of patients, the volume of movements was restored together with the elimination of the pain syndrome, walking time without pain was 45.0 ± 12.7 min. A decrease in lameness was noted in 64.2% of the patients. The duration of the result is 6.8 ± 1.4 months. Clinical efficacy of Fermatron 1% injections in both groups of PA and VS patients was comparable.
Conclusion: PA administration of HA can be a method of choice in the treatment of articular pathology. Periarticular administration of Fermatron does not cause complications and is easily feasible.
Key words: osteoarthrosis, hyaluronic acid, paraarticular administration, Fermatron.
For citation: Popov V.P., Koroshchenko S.A., Larin M.A. Optimal use of hyaluronic acid for joint pathology treatment // RMJ. MEDICAL REVIEW. 2017. № 1. P. 12–14.
References
1. Насонова В.А. Проблема остеоартроза в начале XXI века // Consilium Medicum. 2000. № 2(6). С. 61–64 [Nasonova V.A. Problema osteoartroza v nachale XXI veka // Consilium Medicum. 2000. № 2(6). S. 61–64 (in Russian)].
2. Балабанова Р.М. Место препаратов гиалуроновой кислоты в терапии остеоартроза // Современная ревматология. 2014. № 8 (3). С. 73–76 [Balabanova R.M. Mesto preparatov gialuronovoj kisloty v terapii osteoartroza // Sovremennaja revmatologija. 2014. № 8 (3). S. 73–76 (in Russian)].
3. Dougados M. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect // Semin Arthritis Rheum. 2000. Vol. 30 (2 Suppl 1). P. 19–25.
4. Страхов М.А., Скороглядов А.В., Костив И.М. и др. Использование низкомолекулярных препаратов связанной гиалуроновой кислоты у спортсменов с болевым синдромом внесуставной локализации // Поликлиника. 2013. № 2(1). С. 1–7 [Strahov M.A., Skorogljadov A.V., Kostiv I.M. i dr. Ispol'zovanie nizkomolekuljarnyh preparatov svjazannoj gialuronovoj kisloty u sportsmenov s bolevym sindromom vnesustavnoj lokalizacii // Poliklinika. 2013. № 2(1). S. 1–7 (in Russian)].
5. Stucki G., Meier D., Stucki S. et al. Evaluation of a German version of WOMAC (Western Ontario and McMaster Universities) Arthrosis Index // Z. Rheumatol. 1996. Vol. (55). P. 40–49.
6. Bannuru R.R., Schmid C.H., Kent D.M. et al. Сomparative effectiveness of pharmacologic interventions of knee osteoarthritis: a systematic review and network meta-analysis // Ann Intern Med. 2015. P. 46–54. doi: 10/7326/M14-1231.
7. Waddell B.S., Waddell W.H., Waddell D.D. Comparision of Efficacy and Tolerability of Hylan G-F 20 in Patients with and without Effusions at the Time of Initial Injection // J Knee Surg. 2015. Vol. 28(3). P. 213–222. doi: 10.1055/s-0034-1376328. Epub 2014 May 7.
2. Балабанова Р.М. Место препаратов гиалуроновой кислоты в терапии остеоартроза // Современная ревматология. 2014. № 8 (3). С. 73–76 [Balabanova R.M. Mesto preparatov gialuronovoj kisloty v terapii osteoartroza // Sovremennaja revmatologija. 2014. № 8 (3). S. 73–76 (in Russian)].
3. Dougados M. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect // Semin Arthritis Rheum. 2000. Vol. 30 (2 Suppl 1). P. 19–25.
4. Страхов М.А., Скороглядов А.В., Костив И.М. и др. Использование низкомолекулярных препаратов связанной гиалуроновой кислоты у спортсменов с болевым синдромом внесуставной локализации // Поликлиника. 2013. № 2(1). С. 1–7 [Strahov M.A., Skorogljadov A.V., Kostiv I.M. i dr. Ispol'zovanie nizkomolekuljarnyh preparatov svjazannoj gialuronovoj kisloty u sportsmenov s bolevym sindromom vnesustavnoj lokalizacii // Poliklinika. 2013. № 2(1). S. 1–7 (in Russian)].
5. Stucki G., Meier D., Stucki S. et al. Evaluation of a German version of WOMAC (Western Ontario and McMaster Universities) Arthrosis Index // Z. Rheumatol. 1996. Vol. (55). P. 40–49.
6. Bannuru R.R., Schmid C.H., Kent D.M. et al. Сomparative effectiveness of pharmacologic interventions of knee osteoarthritis: a systematic review and network meta-analysis // Ann Intern Med. 2015. P. 46–54. doi: 10/7326/M14-1231.
7. Waddell B.S., Waddell W.H., Waddell D.D. Comparision of Efficacy and Tolerability of Hylan G-F 20 in Patients with and without Effusions at the Time of Initial Injection // J Knee Surg. 2015. Vol. 28(3). P. 213–222. doi: 10.1055/s-0034-1376328. Epub 2014 May 7.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
